October 7, 2018 - Patient Worthy

A Marketing Application for the Gene Therapy LentiGlobin as a Treatment for Beta-Thalassemia is Being Reviewed in Europe

Post author:Anna Hewitt
Post published:October 7, 2018
Post category:Beta Thalassemia

According to a recent press release from Bluebird Bio, the European Medicines Agency has accepted and will review their marketing authorization application (MAA) for the investigational gene therapy LentiGlobin™ as…

geralt / Pixabay

Treatment For Glioblastoma Gets Orphan Drug Designation

Post author:James Moore
Post published:October 7, 2018
Post category:Glioblastoma

According to a story from MarketWatch, the biopharmaceutical company MediciNova recently announced that the company's product ibudilast was granted Orphan Drug designation by the FDA. The designation was granted for…

A Marketing Application for the Gene Therapy LentiGlobin as a Treatment for Beta-Thalassemia is Being Reviewed in Europe

Treatment For Glioblastoma Gets Orphan Drug Designation

The Let’s Chat CAR T One-on-One Mentor Program: Speaking with Someone Who Understands What You Are Going Through

“Shades of Psoriasis”: Plaque Psoriasis and Sharing Your Story

Understanding RSV: Why Combatting Ethnic and Age-Related Health Disparities Could Improve Outcomes

We Need Equity and Diversity Within Rare Disease Research

DNA in Color: How Ronya Nelson is Working to Close the Diversity Gap in Genetics - Part 1

Bridging the Diversity Gap in Healthcare

Congratulations to the 2023 Recipients of the Diversity in Lupus Research Awards!

Welcome to Study of the Week. We go in-depth and select a study we think is of particular interest, discussing details, explaining its importance, who may be impacted and lots more!

Let’s Work Together!

Keep Up to Date

Learn More